Sun, Sep 21, 2014, 8:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Dec 3, 2012 10:18 AM Flag

    What’s on the Agenda? Isis To Provide Update On Its Metabolic Franchise Pfizer or BM Squibb?

    Witness the latest results coming from research in this field and learn from the leading companies who are proving cancer metabolism to be a field that delivers effective, successful and lucrative cancer therapeutics.

    Discover novel targets and therapeutic opportunities being explored by Pfizer, Bristol-Myers Squibb,

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Push your cancer metabolism drugs though the clinic and towards therapeutic success
      Cancer metabolism has been hailed as cancer’s weak spot. And with deals and collaborations occurring across the industry, the field has grabbed the attention of drug developers worldwide…

      Target Cancer Metabolism is the only meeting where you will be able to meet the leading companies working in this space, all focused on translating cancer metabolism into effective therapies. This meeting will provide you with the opportunity to learn from leading drug developers, and apply their winning techniques to optimise your own pipeline.

      With clinical case studies from some of the most advanced cancer metabolism drugs, this meeting will enable you to understand how pharma and biotechs are translating cancer metabolism research into their internal drug development programs and learn how to apply novel technologies to speed up your drug discovery practices.

      Sentiment: Strong Buy

 
ISIS
42.28+0.40(+0.96%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.